Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Fiduciary Trust Co

Fiduciary Trust Co lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 9.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,160 shares of the pharmaceutical company's stock after purchasing an additional 1,147 shares during the period. Fiduciary Trust Co's holdings in Vertex Pharmaceuticals were worth $5,299,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of VRTX. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals in the 4th quarter worth $30,000. Sugar Maple Asset Management LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $35,000. Golden State Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $37,000. Truvestments Capital LLC raised its position in shares of Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after acquiring an additional 23 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in Vertex Pharmaceuticals by 108.2% in the fourth quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company's stock valued at $41,000 after acquiring an additional 53 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on VRTX shares. BMO Capital Markets set a $545.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Cantor Fitzgerald restated an "overweight" rating and issued a $535.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Leerink Partners reaffirmed a "market perform" rating and set a $503.00 price target (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Truist Financial increased their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Finally, Piper Sandler lowered their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Thirteen research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $515.04.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total transaction of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. This represents a 0.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,005 shares of company stock worth $1,978,465 over the last 90 days. Company insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Trading Up 2.5%

Shares of VRTX stock traded up $10.73 on Thursday, hitting $431.89. The stock had a trading volume of 946,362 shares, compared to its average volume of 1,403,634. The company's 50 day moving average price is $485.28 and its 200-day moving average price is $465.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The firm has a market capitalization of $110.91 billion, a P/E ratio of -196.38, a P/E/G ratio of 2.11 and a beta of 0.51.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. The firm had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. During the same period in the previous year, the firm posted $4.76 earnings per share. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. Analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.